Using Mobile Technology (pMOTAR) to Assess Reactogenicity: Protocol for a Pilot Randomized Controlled Trial

Kathryn Therese Mngadi, Bhavna Maharaj, Yajna Duki, Douglas Grove, Jessica Andriesen, Kathryn Therese Mngadi, Bhavna Maharaj, Yajna Duki, Douglas Grove, Jessica Andriesen

Abstract

Background: Accurate safety monitoring in HIV vaccine trials is vital to eventual licensure and consequent uptake of products. Current practice in preventive vaccine trials, under the HIV Vaccine Trials Network (HVTN), is to capture related side effects in a hardcopy tool. The reconciliation of this tool, 2 weeks after vaccination at the safety visit, is time consuming, laborious, and fraught with error. Unstructured Supplementary Service Data (USSD), commonly used to purchase airtime, has been suggested for collection of safety data in vaccine trials. With saturated access to mobile phones in South Africa, this cheap, accessible tool may improve accuracy and completeness of collected data and prove feasible and acceptable over the hardcopy tool.

Objective: The objective of our study is to develop and implement a USSD tool for real-time safety data collection that is feasible and acceptable to participants and staff, allowing for a comparison with the hardcopy tool in terms of completeness and accuracy.

Methods: This feasibility study is being conducted at a single study site, the Centre for the AIDS Programme of Research in South Africa eThekwini Clinical Research site, in South Africa. The feasibility study is nested within a parent phase 1/2a preventive HIV vaccine trial (HVTN 108) as an open-label, randomized controlled trial, open to all consenting parent trial participants. Participants are randomly assigned in a 1:1 ratio to the hardcopy or USSD tool, with data collection targeted to the third and fourth injection time points in the parent trial. Online feasibility and acceptability surveys will be completed by staff and participants at the safety visit. We will itemize and compare error rates between the hardcopy tool and the USSD printout and associated source documentation. We hypothesize that the USSD tool will be shown to be feasible and acceptable to staff and participants and to have superior quality and completion rates to the hardcopy tool.

Results: The study has received regulatory approval. We have designed and developed the USSD tool to include all the data fields required for reactogenicity reporting. Online feasibility and accessibility surveys in both English and isiZulu have been successfully installed on a tablet. Data collection is complete, but analysis is pending.

Conclusions: Several HIV preventive vaccine trials are active in Southern Africa, making tools to improve efficiencies and minimize error necessary. Our results will help to determine whether the USSD tool can be used in future vaccine studies and can eventually be rolled out.

Trial registration: ClincalTrials.gov NCT02915016; https://ichgcp.net/clinical-trials-registry/NCT02915016 (Archived by WebCite at http://www.webcitation.org/71h0cztDM).

Registered report identifier: RR1-10.2196/9396.

Keywords: AIDS vaccines; HIV preventive vaccines; mobile applications; mobile health application; research protocol; telemedicine.

Conflict of interest statement

Conflicts of Interest: None declared.

©Kathryn Therese Mngadi, Bhavna Maharaj, Yajna Duki, Douglas Grove, Jessica Andriesen. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 03.10.2018.

Figures

Figure 1
Figure 1
The Sample Unstructured Supplementary Service Data Tool (string 1).
Figure 2
Figure 2
Part 1 of the Sample Unstructured Supplementary Service Data Tool (string 2).
Figure 3
Figure 3
Part 2 of the Sample Unstructured Supplementary Service Data Tool (string 2).
Figure 4
Figure 4
Part 3 of the Sample Unstructured Supplementary Service Data Tool (string 2).
Figure 5
Figure 5
Sample hardcopy tool (page 1).
Figure 6
Figure 6
Sample hardcopy tool (page 2).
Figure 7
Figure 7
Sample hardcopy tool (page 3).

References

    1. UNAIDS Global AIDS report. 2016. [2018-02-17].
    1. Medicines Control Council approves fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine for pre-exposure prophylaxis of HIV [press release] Pretoria, South Africa: Department of Health; 2015.
    1. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines. 2010 Sep;9(9):997–1005. doi: 10.1586/erv.10.104.
    1. Kimmel SR. Vaccine adverse events: separating myth from reality. Am Fam Physician. 2002 Dec 01;66(11):2113–20.
    1. Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, Sulway C, Wilson K. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004 Nov 19;18(17):2235–42.
    1. Muehlhans S, Richard G, Ali M, Codarini G, Elemuwa C, Khamesipour A, Maurer W, Mworozi E, Kochhar S, Rundblad G, Vuitton D, Rath B. Safety reporting in developing country vaccine clinical trials-a systematic review. Vaccine. 2012 May 09;30(22):3255–65. doi: 10.1016/j.vaccine.2012.02.059.
    1. Tamminga C, Kavanaugh M, Fedders C, Maiolatesi S, Abraham N, Bonhoeffer J, Heininger U, Vasquez CS, Moorthy VS, Epstein JE, Richie TL. A systematic review of safety data reporting in clinical trials of vaccines against malaria, tuberculosis, and human immunodeficiency virus. Vaccine. 2013 Aug 02;31(35):3628–35. doi: 10.1016/j.vaccine.2013.01.045.
    1. Catalani C, Philbrick W, Fraser H, Mechael P, Israelski DM. mHealth for HIV treatment & prevention: a systematic review of the literature. Open AIDS J. 2013;7:17–41. doi: 10.2174/1874613620130812003.
    1. Devi BR, Syed-Abdul S, Kumar A, Iqbal U, Nguyen P, Li YJ, Jian W. mHealth: an updated systematic review with a focus on HIV/AIDS and tuberculosis long term management using mobile phones. Comput Methods Programs Biomed. 2015 Nov;122(2):257–65. doi: 10.1016/j.cmpb.2015.08.003.
    1. Labrique A, Vasudevan L, Chang LW, Mehl G. H_pe for mHealth: more "y" or "o" on the horizon? Int J Med Inform. 2013 May;82(5):467–9. doi: 10.1016/j.ijmedinf.2012.11.016.
    1. Young SD, Holloway IW, Swendeman D. Incorporating guidelines for use of mobile technologies in health research and practice. Int Health. 2014 Jun;6(2):79–81. doi: 10.1093/inthealth/ihu019.
    1. Littman-Quinn R, Luberti AA, Kovarik C. mHealth to revolutionize information retrieval in low and middle income countries: introduction and proposed solutions using Botswana as reference point. Stud Health Technol Inform. 2013;192:894–8.
    1. Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev. 2012;3:CD009756. doi: 10.1002/14651858.CD009756.
    1. Mukund BK, Murray PJ. Cell phone short messaging service (SMS) for HIV/AIDS in South Africa: a literature review. Stud Health Technol Inform. 2010;160(Pt 1):530–4.
    1. Bronkhorst Q. Mobile subscribers in SA: who’s eating whose lunch? Lyttelton, South Africa: BusinessTech Newsletter; 2013. Aug 14, [2018-08-14].
    1. National Department of Health eHealth Strategy South Africa. [2018-02-17]. .
    1. Department of Health . Guidelines for Good Practice in the Conduct of Clinical Trials With Human Participants in South Africa. Second edition. Pretoria, South Africa: Department of Health; 2006. [2018-08-14]. .
    1. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 2.0. Bethesda, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services; 2014. Nov,

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere